Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric P Krenning

Showing results (71-80 of 173) with videos related to

Pageof 18
Sort By:
Nature Reviews. Endocrinology|June 3, 2009
Peptide-receptor radionuclide therapy for endocrine tumorsMartijn van Essen, Eric P Krenning, Boen L R Kam, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2004
Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analogAstrid Capello, Eric P Krenning, Bert F Bernard, et al.
Neuroendocrinology|August 29, 2009
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogsDik J Kwekkeboom, Eric P Krenning, Rachida Lebtahi, et al.
Hormone Research|June 10, 2009
Bone mineral density and body composition in adolescents with childhood-onset growth hormone deficiencyAnnemieke M Boot, Inge M van der Sluis, Eric P Krenning, et al.
Pharmaceutics|December 1, 2020
One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [<sup>99m</sup>Tc]Tc-DB4 and [<sup>111</sup>In]In-SG4 in Mice Treated with EntrestoPanagiotis Kanellopoulos, Aikaterini Kaloudi, Maritina Rouchota, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogsStanislas Pauwels, Raffaella Barone, Stéphan Walrand, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 5, 2007
Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidneyEdgar J Rolleman, Peter P M Kooij, Wouter W de Herder, et al.
Hematology/Oncology Clinics of North America|June 6, 2007
Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analoguesDik J Kwekkeboom, Jaap J M Teunissen, Boen L Kam, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 6, 2006
Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotateEdgar J Rolleman, Flavio Forrer, Bert Bernard, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 13, 2011
Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?Stephan Walrand, Glenn D Flux, Mark W Konijnenberg, et al.
Pageof 18

Showing results (71-80 of 173) with videos related to

Sort By:
Pageof 18
Nature Reviews. Endocrinology|June 3, 2009
Peptide-receptor radionuclide therapy for endocrine tumorsMartijn van Essen, Eric P Krenning, Boen L R Kam, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2004
Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analogAstrid Capello, Eric P Krenning, Bert F Bernard, et al.
Neuroendocrinology|August 29, 2009
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogsDik J Kwekkeboom, Eric P Krenning, Rachida Lebtahi, et al.
Hormone Research|June 10, 2009
Bone mineral density and body composition in adolescents with childhood-onset growth hormone deficiencyAnnemieke M Boot, Inge M van der Sluis, Eric P Krenning, et al.
Pharmaceutics|December 1, 2020
One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [<sup>99m</sup>Tc]Tc-DB4 and [<sup>111</sup>In]In-SG4 in Mice Treated with EntrestoPanagiotis Kanellopoulos, Aikaterini Kaloudi, Maritina Rouchota, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogsStanislas Pauwels, Raffaella Barone, Stéphan Walrand, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 5, 2007
Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidneyEdgar J Rolleman, Peter P M Kooij, Wouter W de Herder, et al.
Hematology/Oncology Clinics of North America|June 6, 2007
Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analoguesDik J Kwekkeboom, Jaap J M Teunissen, Boen L Kam, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 6, 2006
Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotateEdgar J Rolleman, Flavio Forrer, Bert Bernard, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 13, 2011
Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?Stephan Walrand, Glenn D Flux, Mark W Konijnenberg, et al.
Pageof 18